Will Pizii | Authors

June 07, 2022

Patients enrolled on the phase 3 ENGOT-EN5/GOG-3055/SIENDO study with advanced or recurrent endometrial cancer appeared to benefit from treatment with selinexor compared with placebo.

June 05, 2022

Distant metastasis-free and recurrence-free survival were better in patients with resected stage II melanoma who were treated with adjuvant pembrolizumab vs placebo.

April 25, 2022

Serious graft-versus-host disease may be prevented with the prolonged use of ruxolitinib after hematopoietic cell transplantation.

April 11, 2022

Results of CheckMate 649 trial show consistently improved outcomes across advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma when nivolumab is administered in combination with chemotherapy.

February 20, 2022

A surrogate for toxicity and drug exposure, cabozantinib dose reductions were tied to longer durations of time to treatment failure and overall survival for patients with metastatic renal cell carcinoma.

February 19, 2022

At 2022 ASCO GU, early trial results show promise for fluorodeoxyglucose and sodium fluoride PET/CT prognostic ability to predict survival in patients with metastatic genitourinary malignancies treated with cabozantinib plus PD-1/CTLA-3 inhibition.

January 23, 2022

The CheckMate 9X8 trial did not hit the primary end point of progression-free survival superiority with nivolumab plus standard of care vs standard of care alone in metastatic colorectal cancer.

January 23, 2022

Treatment with trastuzumab deruxtecan produced promising efficacy results for patients with HER2-positive metastatic colorectal cancer.

December 14, 2021

Patients with high-risk large B-cell lymphoma saw durable responses when treated with axicabtagene ciloleucel.

December 12, 2021

Durable clinical responses were demonstrated with the use of parsaclisib in patients with relapsed or refractory marginal zone lymphoma.